in 25 of 28 (89%) patients, with median viral load 4.7 (range, 2.0-6.7) log 10 copies/mL, and subsequently declined in most patients. At 12 months, overall survival was 75% (95% confidence interval [CI], 55%-88%) and progression-free survival 65% (95% CI, 42%-81%). Baseline plasma EBV DNA and persistent viremia during treatment were associated with poorer outcomes.
INTRODUCTION
In sub-Saharan Africa (SSA), classical Hodgkin lymphoma (cHL) is a common malignancy among children and young adults, accounting for 4%-9% of pediatric cancers. [1] [2] [3] Given limited pathology infrastructure, cHL is also likely underreported since gradually progressive lymphadenopathy may be empirically treated as tuberculosis, leading to delayed or missed cHL diagnosis. [3] [4] [5] In resource-rich countries, 75% of newly diagnosed patients present with early stage I/II cHL, 6, 7 while in resource-limited countries, more than half of patients present with advanced stage III/IV disease. 2 In resource-rich settings, cHL is highly curable with greater than 90% long-term survival for stage I/II and 80% for stage III/IV. 8 Although data are scarce, reported survival rates for cHL in SSA are lower ranging from 60% to 70%. 3, 9 In resource-rich settings, cHL is one of the commonest non-AIDS defining cancers among individuals infected with human immunodeficiency virus (HIV). 10 Despite reductions in other HIV-associated lymphoma subtypes, the incidence of cHL appears stable or increasing in the current antiretroviral therapy (ART) era. 9, [11] [12] [13] [14] [15] [16] [17] Moreover, the risk of HIV-associated cHL may be increased in the first months after ART initiation due to immune reconstitution. 12, 17, 18 Studies in the United States have shown that cHL incidence is 5-20 times higher among HIV+ patients, with 3%-4% of newly diagnosed cHL cases occurring in HIV-infected individuals. [11] [12] [13] 19 HIV-infected individuals with cHL are more likely to present with advanced stage, B symptoms, and extranodal involvement. 10, 11, 19 However, when treated appropriately, cHL patients with HIV can receive similar regimens and experience comparable outcomes to those without HIV. 12, 20, 21 cHL is also often associated with Epstein-Barr virus (EBV), 22 an oncogenic herpesvirus that infects more than 80% of children in SSA typically before 5 years of age. 23 The frequency of EBV-positive cHL differs geographically, being more common in resource-limited regions of the world including SSA where 70%-90% of cHL cases are EBVpositive. 3, 22, 24 EBV-positive cHL is also more common in children, males, and HIV-infected individuals. 10, 12, 22, 24 Although cHL is a common cancer frequently associated with HIV and EBV, both of which are highly prevalent in SSA, to our knowledge there are no prospective clinical studies of cHL from SSA from the contemporary era of widespread ART availability. Herein we describe clinical characteristics, treatment course, HIV and EBV associations, and survival for a longitudinal cHL cohort at Kamuzu Central Hospital (KCH), a national teaching hospital in the Malawian capital, Lilongwe.
It serves approximately 8-9 million people in a country with an HIV prevalence of 10%, ART coverage of 67%, 25 annual gross domestic product per capita of 314 US dollars, 26 and Human Development Index rank of 173 of 188 countries. 27 
METHODS
The KCH Lymphoma Study is a prospective cohort initiated in June All cases were diagnosed through weekly telepathology consultation involving two to four pathologists in Malawi and the United States who rendered a consensus opinion after reviewing hematoxylin and eosin stained tissue sections. 28, 29 Immunohistochemistry (IHC) was performed locally at the interpreting pathologists' discretion, including CD3, CD20, CD30, CD45, CD138, Ki-67, and terminal deoxynucleotidyl transferase. In rare pediatric cases, a cytologic diagnosis of cHL was made when clinical findings were consistent and binucleated Reed-Sternberg cells were clearly identified, only when tissue biopsy was not possible due to anatomic location and limited pediatric surgery capacity. All specimens were then shipped to the United States for secondary hematopathologist review, where diagnoses were con- Baseline characteristics were summarized using descriptive statistics. Follow-up time was calculated from enrollment until progression or death, loss to follow-up, or administrative censoring on May 15, 2016 . Overall survival and progression-free survival were estimated using Kaplan-Meier methods, and the log-rank test was used to assess survival differences between groups. Cox proportional hazards were used to estimate unadjusted hazard ratios for overall survival and progression-free survival. The cause of death was adjudicated by consensus review involving two study investigators (K.D.W. and S.G.). All analyses were performed using STATA SE version 12.1 (College Station, TX).
RESULTS

Baseline characteristics
Between June 1, 2013, and December 31, 2015, 31 patients (11%) with cHL were enrolled of 274 total patients with pathologically confirmed lymphoproliferative disorders in the cohort overall. During the study period, we were aware of three cases, all children, diagnosed with Hodgkin lymphoma who were not enrolled in the study for the following reasons: one child died before the pathologic diagnosis was confirmed, one child's family elected not be participate, and one child was diagnosed during a brief enrollment pause resulting from minor administrative delay in obtaining annual Malawi regulatory renewal for the study.
Baseline characteristics for patients with cHL are shown in Table 1 .
The median age was 19 years (range, 2-51 years) and 22 (71%) were male. A total of 16 patients (52%) had stage III/IV disease, 25 (81%) B symptoms, and 16 (52%) significant performance status impairment. Of 26 patients with primary sites that could be accurately measured, 11 (42%) had bulky disease. 32, 33 Twenty-three of 31 patients (74%) had symptom durations greater than 6 months at cHL diagnosis, and 11 of 29 (38%) had received empiric antituberculosis treatment for lymphadenopathy. Eleven of 31 patients (35%) were significantly underweight. Anemia was common with median hemoglobin 8. 
Treatment course and toxicities
As of May 15, 2016 , the median number of cycles completed for all 31 patients was 7 (range, 1-8). Twenty-one (68%) patients completed all prescribed chemotherapy, nine (29%) died before treatment completion, and one (3%) was still completing front-line treatment. Table 3 . Overall survival was 75% (95% CI 55%-88%) 12 months after enrollment, and 61% (95% CI 35%-79%) 24 months after enrollment, without significant differences between adults and children. Progression-free survival was 71% (95% CI 42%-81%) 12 months after enrollment, and 56%
(95% CI 14%-68%) 24 months after enrollment. All five HIV-infected Table S1 ). Six deaths were attributed to progressive cHL and three to treatment-related complications.
Of 28 patients with baseline plasma tested for EBV DNA, 25 (89%)
had detectable viremia with a median viral load of 4.7 log 10 copies/mL (range, 2.0-6.7 log 10 copies/mL), which resolved in most patients by the mid-point of chemotherapy treatment (Fig. 2) . While very high plasma EBV DNA was clearly demonstrated in two patients at the time of clinical relapse as shown, a total of six patients including those two cases had increasing plasma EBV DNA at either the chemotherapy mid-point or chemotherapy completion. Of these, five experienced relapse or death during follow-up, with only one patient alive and in remission four months after enrollment. In addition, for patients in whom both baseline plasma EBV DNA and tumor EBER were assessed, results
were strongly correlated, with plasma EBV DNA being detected in 17 of 17 EBER-positive patients versus 4 of 7 EBER-negative patients (P = 0.017).
Our small cohort did not allow robust multivariate assessment of risk factors associated with outcomes. However, in exploratory unadjusted analyses, only increased LDH was associated with increased risk of progression or death in the cohort overall (unadjusted hazard ratio with plasma EBV DNA measurement at the mid-point of chemotherapy, there was a significant association between detectable virus at this time point and worse progression-free survival subsequently (Fig. 3 ).
DISCUSSION
To our knowledge, this is the first prospective clinical description of cHL from SSA reflecting the current ART era for HIV. Our cohort was characterized by advanced stage, poor performance status, long symptom durations prior to cHL diagnosis, frequent empiric treatment for tuberculosis lymphadenitis, and significant anemia. However, both children and adults had reasonably good overall and progression-free survival with standardized treatment in a severely resource-limited environment, irrespective of HIV status.
Marked anemia was a notable feature of our cohort, much more so than our previous Malawi reports of adult and pediatric nonHodgkin lymphoma. 34, 35 Although comprehensive evaluation to identify various causes of anemia was not routinely done unless clinically indicated, hemoglobin improved during treatment, and half of Among adults with cHL, one-third were HIV-infected. All HIVinfected adults were on ART at cHL diagnosis for a median of more than a year, and most had undetectable HIV RNA. cHL may therefore emerge as a more frequent lymphoma subtype in Malawi among HIVinfected individuals, as earlier and more widespread application of ART continues, just as in resource-rich countries. 11 In high-income countries, HIV is present in 3%-4% of cHL cases with higher proportions among lymphocyte-depleted and mixed cellularity subtypes, 13 and it remains unclear whether cHL incidence has changed significantly among HIV-infected individuals in the ART era. [14] [15] [16] [17] In cross-sectional studies from SSA, HIV prevalence has typically been reported as 20%-50% among adults with cHL, [37] [38] [39] and <10% among children, 40, 41 with cHL incidence appearing to be stable thus far despite ART scale-up. 42 We also found strong associations between cHL and EBV as expected, with 75% of cases being EBER-positive and 89% having elevated baseline plasma EBV viral load, similar to other reports from SSA. 3, 22, 24 In resource-rich settings, quantitative plasma EBV DNA has been demonstrated to have potential utility in cHL for diagnosis, prognosis, and monitoring. [43] [44] [45] [46] Although our small cohort allowed only limited assessment of plasma EBV DNA for cHL prognosis and response assessment, to our knowledge, this is the first study from SSA to specifically examine serial EBV viral loads during cHL treatment.
We observed markedly elevated levels at baseline, which declined in the majority of patients during chemotherapy. We also found significant associations between plasma EBV DNA levels at baseline and persistence of plasma EBV DNA at the mid-point of chemotherapy with subsequent progression-free survival. These results deserve further investigation in larger cohorts from the region. If confirmed, EBV viral load could represent an important, clinically implementable biomarker in SSA, a region where capacity for plasma HIV RNA measurement is already well established. 47 Existing HIV RNA instruments in many an approach that is far more implementable at the point of care in lowresource settings. 48 Despite adverse baseline characteristics and a severely resourceconstrained environment, overall survival was 75% at 12 months and 61% at 24 months for the cohort, with generally good outcomes for children and adults irrespective of HIV status. This compares favorably with other reports from SSA settings, 3, 9 and demonstrates that outcomes can be good even in Malawi if patients receive appropriate treatment with standard regimens and careful monitoring.
The strengths of our study include a detailed, prospective cohort with high-quality pathologic diagnoses, protocol-guided treatment, and longitudinal follow-up with standardized assessments. In addition,
we had complete retention and outcome ascertainment. Patient retention in clinical cancer studies in SSA is a major challenge, and survival can be significantly overestimated when patients are lost to follow-up, since death is a major cause of loss to follow-up in this environment.
Finally, all patients received standardized treatment according to institutional guidelines during the study period. The limitations include referral bias at a national teaching hospital, small sample size, lack of systematic evaluation for various causes of anemia, and assigning cause of death based on inference after centralized review. In addition, our cohort was likely understaged relative to cohorts in resource-rich settings due to absent bone marrow evaluation particularly in children and lack of advanced imaging for all patients.
To conclude, cHL occurred primarily among adolescents and young adults in Malawi, typically associated with EBV and often HIV. Despite advanced disease and impaired performance status, children and adults were successfully treated with good short-term outcomes irrespective of HIV status. Survival can likely be further improved through continued efforts to achieve earlier diagnosis and define optimal treatment approaches for cHL in this environment. Such efforts may benefit from further evaluation of plasma EBV DNA as a clinically important and implementable biomarker in Malawi and comparable settings to facilitate better risk-adapted and response-guided therapeutic strategies.
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